Bajaj Healthcare Bags DCGI Nod to Manufacture Pimavanserin API & Formulation

Bajaj Healthcare announced that it has obtained approval from the Drug Controller General of India (DCGI) to produce both the API and drug formulation of Pimavanserin. Pimavanserin is an atypical antipsychotic utilized to treat hallucinations and delusions linked to psychosis in Parkinson's disease.

Pimavanserin, known worldwide as NUPLAZID, has emerged as a favored therapy in the US antipsychotic market. In a recent announcement, Acadia Pharmaceuticals stated that NUPLAZID, together with its other brand DAYBUE, is expected to exceed $1 billion in net sales by 2025.

The company has additionally proposed the production of Pimavanserin to multiple prominent Indian pharmaceutical firms, guaranteeing the products' availability in the local market.

Anil Jain, managing director of Bajaj Healthcare, stated: This approval signifies a significant achievement for Bajaj Healthcare.

The increasing success of NUPLAZID in the US highlights the worldwide need for this groundbreaking treatment, and we believe that its launch in India will represent a significant progress in the antipsychotic market. This action reinforces our position in the central nervous system (CNS) sector and underscores our commitment to improving healthcare solutions in India.

Bajaj Healthcare, a prominent producer of APIs, intermediates, and formulations. It has a significant presence worldwide in regions such as Europe, the USA, Australia, Africa, the Middle East, and South America.